The information provided on EL7.AI is for educational and informational purposes only and does not constitute financial advice.

Stocks•30 April 2026•

1 min read

OSE Immunotherapeutics Reports FY 2025 Results, Confirms Cash Runway into Q4 2026

Key Facts

1The company's cash position stood at €22.7 million at the end of 2025 and €17.0 million as of March 31, 2026.

2The company confirmed its cash runway remains unchanged until early Q4 2026.

3The filing of the 2025 Universal Registration Document is postponed to no later than May 28, 2026, as audit procedures are ongoing.

OSE Immunotherapeutics has released its unaudited financial results for FY 2025, reporting a cash position of €22.7 million at year-end, which adjusted to €17.0 million by March 31, 2026. The company confirmed that its current cash runway remains sufficient to fund operations until the beginning of Q4 2026. Notably, the filing of the 2025 Universal Registration Document has been postponed to no later than May 28, 2026, pending the completion of ongoing audit procedures. This update provides clarity on the firm's financial health while highlighting the limited timeframe for its current capital reserves. Investors are closely monitoring the biotech firm's strategic roadmap as it navigates its clinical development goals. The delay in formal documentation suggests a cautious approach to final financial reporting during this period.